AstraZeneca PLC — Share Issue/Capital Change 2021

Jan 26, 2021

National Storage Mechanism | Additional information

RNS Number : 9583M

AstraZeneca PLC

26 January 2021

26 January 2021 15:00 GMT

Block listing application

A block listing application has been made for 5,000,000 Ordinary Shares of $0.25 each in AstraZeneca PLC (the "Company") to be admitted to the Official List of the Financial Conduct Authority and admitted to trading on the London Stock Exchange.

Admission is expected to become effective on 29 January 2021.

Upon issue, the shares will be fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company and will be issued pursuant to the following employee share plans:

AstraZeneca Share Option Plan

AstraZeneca Savings-Related Share Option Plan

AstraZeneca All-Employee Share Plan

AstraZeneca PLC 2012 Savings-Related Share Option Scheme

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSBFMITMTATBTB